文献速递慢性肾脏病遗传性与小管间质肾病

近端小管重吸收标志物与普通人群CKD进展

Proximal Tubule Reabsorption and CKD Progression in the General Population.
PubMed 文献 · Kidney Int Rep · 2026-01-29

在挪威HUNT-3队列的病例-队列设计中,尿A1M和B2M升高与主要不良肾脏事件风险增加独立相关,而尿CysC无显著关联。A1M与eGFR存在交互作用,在eGFR 45-75 ml/min/1.73m2人群中影响更明显。评估小管健康可能改善CKD分期和风险分层。

要点

  • 尿A1M和B2M与MAKE风险独立于eGFR、白蛋白尿和CKD危险因素相关。
  • 尿CysC与MAKE无显著关联。
  • A1M与eGFR存在交互作用,在eGFR 45-75 ml/min/1.73m2时影响更明显。

核心结论

  • 近端小管重吸收标志物尿A1M和B2M与MAKE风险独立相关,提示评估小管健康可能改善CKD分期和风险分层。

研究设计与样本

  • 采用病例-队列设计,从基于普通人群的挪威HUNT-3研究(2006-2008)中随机抽样1246名成人,并纳入445例随访13年发生MAKE的病例。

主要发现

  • 基线平均年龄53岁(SD 15),平均eGFR 92 ml/min/1.73m2(SD 22),尿白蛋白肌酐比中位数1.3 mg/mmol(IQR 1.0-1.8)。
  • 糖尿病、心血管疾病和治疗高血压的患病率分别为5%、9%和23%。
  • 独立于eGFR、白蛋白尿和CKD危险因素,尿A1M每升高1-SD与MAKE风险增加相关(OR 1.45,95%CI 1.17-1.81)。
  • 尿B2M每升高1-SD与MAKE风险增加相关(OR 1.23,95%CI 1.05-1.44)。
  • 尿CysC与MAKE无显著关联(OR 0.94,95%CI 0.74-1.19);A1M与eGFR存在显著交互作用(P=0.03),在基线eGFR 45-75 ml/min/1.73m2者中A1M对MAKE风险影响更明显。

临床怎么用

  • 在CKD风险评估中,可考虑检测尿A1M和B2M以补充eGFR和白蛋白尿的不足。
  • 对eGFR 45-75 ml/min/1.73m2的人群,尿A1M可能有助于识别MAKE高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Current markers of chronic kidney disease (CKD) primarily reflect kidney glomerular health and do not include markers of kidney tubule health. METHODS: We used a case-cohort design with 1246 adults randomly sampled from the general population-based Trøndelag health study (HUNT)-3 study (Norway, 2006-2008) and 445 cases experiencing major adverse kidney events (MAKE; progressive CKD [n = 341], rapid estimated glomerular filtration rate [eGFR] decline [n = 232], kidney replacement therapy [KRT, n = 10], or kidney death [n = 9]) during 13 years of follow-up. Associations of proximal tubule reabsorption markers in the urine (alpha-1-microglobulin [A1M], beta-2-microglobulin [B2M], and cystatin C [CysC]) with MAKE were evaluated using weighted logistic regression analyses. RESULTS: At baseline, mean age was 53 years (SD: 15), eGFR was 92 ml/min per 1.73 m2 (SD: 22), and median urine albumin-creatinine-ratio was 1.3 mg/mmol (interquartile range [IQR]: 1.0-1.8). The prevalence of diabetes, cardiovascular disease (CVD), and treated hypertension was 5%, 9%, and 23%, respectively. Independent of eGFR, albuminuria, and CKD risk factors, each 1-SD higher urine A1M and B2M were associated with greater odds of MAKE (odds ratio [OR]: 1.45, 95% confidence interval [CI]: 1.17-1.81 and OR: 1.23, 95% CI: 1.05-1.44, respectively). No significant association was observed for urine CysC (OR: 0.94, 95% CI: 0.74-1.19). There was significant interaction between A1M and eGFR (P = 0.03), and 2-way sensitivity analysis displayed that levels of urine A1M particularly influenced the MAKE risk in those with eGFR of 45 to 75 ml/min per 1.73 m2 at baseline. CONCLUSION: The proximal tubule reabsorption markers, urine A1M and B2M, were associated with MAKE beyond eGFR, albuminuria, and CKD risk factors. Assessing tubule health may improve CKD staging and risk stratification.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Øvrehus M, Ikeme J, Katz R, et al. Proximal Tubule Reabsorption and CKD Progression in the General Population. Kidney Int Rep. 2026. PMID: 41799361. doi:10.1016/j.ekir.2026.103801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。